Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic cancer

Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic cancer - modified FOLFIRINOX Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015376

Enrollment

Registered

2014-10-08

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced pancreatic cancer

Interventions

modified FOLFIRINOX

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histological or cytologically proved pancreatic cancer adenocarcinoma or adenosquamous carcinoma Inoperative cases of advanced pancreatic cancer Without other chemotherapy or radiotherapy Age 20-75 years ECOG Performance Status (PS) 0-1 Meets the following criteria within 14 days before enrollment absolute neutrophil count <2000/microl, platelet count <100,00/microl, hemoglobin <9g/dl, bilirubin >2.0mg/dl, AST and ALT >150U/l, Creatinine >1.2mg/dl, Creatinine clearance test <50ml/min Hemotype of UGT1A1 genotype is not including *6/*6, *28/*28, and *6/*28 Without anorexia Normal ECG An agreement is provided

Exclusion criteria

Exclusion criteria: Pulmonary fibrosis or interstitial pneumonia Watery stool Infection Uncontrolled diabetes mellitus Any serious complication Use of Atazanavir, Flucytosine, Phenytoin, and Warfarin potassium Pregnancy

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Overall survival Progression free survival The frequency of occurrence of complication	—

Countries

Japan

Contacts

Public ContactMitsuru Okuno

Gifu University Hospital First Department of internal Medicine

mkobdkl@yahoo.co.jp058-230-6308

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026